NEW YORK – Hutchmed on Wednesday said it started a Phase I/IIa trial of its antibody-targeted therapy conjugate (ATTC) HMPL-A580 in patients with unresectable, advanced or metastatic solid tumors.
1 Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan 2 Laboratory of Molecular and Cellular Medicine, Faculty of Pharmaceutical Sciences, ...
Tyra Biosciences Inc. has disclosed new indazole compounds acting as fibroblast growth factor receptor (FGFR) inhibitors. They are reported to be useful for the treatment of cancer and developmental ...
A BridgeBio Pharma drug developed for dwarfism increased children’s growth rates in a pivotal clinical trial, meeting the study’s main goal and boosting the daily pill’s chances to offer an ...
NEW YORK – Amgen on Tuesday said it would not seek regulatory approval for its investigational FGFR2b-targeting monoclonal antibody bemarituzumab as a first-line treatment for FGFR2b-overexpressing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results